Beigene Stock Performance
| BGNE Stock | USD 162.25 0.24 0.15% |
On a scale of 0 to 100, BeiGene holds a performance score of 6. The firm shows a Beta (market volatility) of 2.09, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, BeiGene will likely underperform. Please check BeiGene's standard deviation, value at risk, kurtosis, as well as the relationship between the sortino ratio and semi variance , to make a quick decision on whether BeiGene's price patterns will revert.
Risk-Adjusted Performance
6 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in BeiGene are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady basic indicators, BeiGene exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.15 | Five Day Return 4.68 | Year To Date Return (8.33) | Ten Year Return 472.92 | All Time Return 472.92 |
1 | BeiGene CHMP Tislelizumab | 02/27/2024 |
2 | Disposition of 82020 shares by Donald Glazer of BeiGene subject to Rule 16b-3 | 03/11/2024 |
3 | Disposition of 200 shares by John Oyler of BeiGene at 169.05 subject to Rule 16b-3 | 03/12/2024 |
4 | The Max FoundationBeiGeneBeiGene FoundationBRUKINSA | 03/14/2024 |
5 | Disposition of 14677 shares by Ball Titus B. of BeiGene at 15.97 subject to Rule 16b-3 | 03/19/2024 |
6 | Disposition of 111 shares by Wang Lai of BeiGene at 225.2721 subject to Rule 16b-3 | 03/25/2024 |
7 | Disposition of 4099 shares by Xiaodong Wang of BeiGene at 260.305 subject to Rule 16b-3 | 03/26/2024 |
8 | BofA cuts BeiGene stock PT, cites sales and competition concerns | 04/08/2024 |
9 | Disposition of 7924 shares by John Oyler of BeiGene at 154.2084 subject to Rule 16b-3 | 04/09/2024 |
10 | Disposition of tradable shares by John Oyler of BeiGene at 150.85 subject to Rule 16b-3 | 04/10/2024 |
11 | BeiGene CEO John Oyler sells shares worth over 7.4 million | 04/11/2024 |
12 | BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer | 04/23/2024 |
13 | Resumen BeiGene, innovador internacional en oncologa, presenta nuevos datos sobre su gama de productos de hematologa y tumores slidos en el congreso anual de AS... | 04/25/2024 |
14 | Amgen posts Q1 revenue and earnings beat Stock down 2 | 05/02/2024 |
| Begin Period Cash Flow | 3.9 B |
BeiGene |
BeiGene Relative Risk vs. Return Landscape
If you would invest 14,181 in BeiGene on February 5, 2024 and sell it today you would earn a total of 2,044 from holding BeiGene or generate 14.41% return on investment over 90 days. BeiGene is currently generating 0.2643% in daily expected returns and assumes 3.33% risk (volatility on return distribution) over the 90 days horizon. In different words, 29% of stocks are less volatile than BeiGene, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BeiGene Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BeiGene's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BeiGene, and traders can use it to determine the average amount a BeiGene's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0794
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BGNE | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.33 actual daily | 29 71% of assets are more volatile |
Expected Return
| 0.26 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average BeiGene is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BeiGene by adding it to a well-diversified portfolio.
BeiGene Fundamentals Growth
BeiGene Stock prices reflect investors' perceptions of the future prospects and financial health of BeiGene, and BeiGene fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BeiGene Stock performance.
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.36) % | ||||
| Operating Margin | (0.61) % | ||||
| Current Valuation | 218.34 B | ||||
| Shares Outstanding | 104.54 M | ||||
| Price To Earning | (16.19) X | ||||
| Price To Book | 4.17 X | ||||
| Price To Sales | 6.34 X | ||||
| Revenue | 2.46 B | ||||
| Gross Profit | (511.06 M) | ||||
| EBITDA | (1.12 B) | ||||
| Net Income | (881.71 M) | ||||
| Cash And Equivalents | 5.7 B | ||||
| Cash Per Share | 55.17 X | ||||
| Total Debt | 930.18 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 4.54 X | ||||
| Book Value Per Share | 33.83 X | ||||
| Cash Flow From Operations | (1.16 B) | ||||
| Earnings Per Share | (8.45) X | ||||
| Market Capitalization | 17.68 B | ||||
| Total Asset | 5.81 B | ||||
| Retained Earnings | (7.96 B) | ||||
| Working Capital | 2.39 B | ||||
| Current Asset | 106.27 M | ||||
| Current Liabilities | 35.17 M | ||||
About BeiGene Performance
To evaluate BeiGene Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when BeiGene generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare BeiGene Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand BeiGene market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents BeiGene's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 327.44 | 343.81 | |
| Return On Tangible Assets | (0.15) | (0.16) | |
| Return On Capital Employed | (0.30) | (0.32) | |
| Return On Assets | (0.15) | (0.16) | |
| Return On Equity | (0.25) | (0.26) |
Things to note about BeiGene performance evaluation
Checking the ongoing alerts about BeiGene for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BeiGene help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BeiGene had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 2.46 B. Net Loss for the year was (881.71 M) with loss before overhead, payroll, taxes, and interest of (511.06 M). | |
| BeiGene currently holds about 5.7 B in cash with (1.16 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 55.17. | |
| BeiGene has a poor financial position based on the latest SEC disclosures | |
| Roughly 20.0% of the company shares are held by company insiders | |
| Latest headline from investing.com: Amgen posts Q1 revenue and earnings beat Stock down 2 |
- Analyzing BeiGene's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BeiGene's stock is overvalued or undervalued compared to its peers.
- Examining BeiGene's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BeiGene's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BeiGene's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BeiGene's stock. These opinions can provide insight into BeiGene's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BeiGene. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade BeiGene Stock refer to our How to Trade BeiGene Stock guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for BeiGene Stock analysis
When running BeiGene's price analysis, check to measure BeiGene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BeiGene is operating at the current time. Most of BeiGene's value examination focuses on studying past and present price action to predict the probability of BeiGene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BeiGene's price. Additionally, you may evaluate how the addition of BeiGene to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |
Is BeiGene's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BeiGene. If investors know BeiGene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BeiGene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.45) | Revenue Per Share 23.554 | Quarterly Revenue Growth 0.669 | Return On Assets (0.12) | Return On Equity (0.22) |
The market value of BeiGene is measured differently than its book value, which is the value of BeiGene that is recorded on the company's balance sheet. Investors also form their own opinion of BeiGene's value that differs from its market value or its book value, called intrinsic value, which is BeiGene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BeiGene's market value can be influenced by many factors that don't directly affect BeiGene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BeiGene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BeiGene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BeiGene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.